CEP-7055

• CAT Number: I005957
• CAS Number: 402857-58-3
• Molecular Formula: C32H35N3O4
• Molecular Weight: 525.65
• Purity: ≥95%
• Synonyms: CEP7055; CEP-7055; CEP 7055.;Glycine, N,N-dimethyl-, 3-[5,6,7,13-tetrahydro-9-[(1-methylethoxy)methyl]-5-oxo-12H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-12-yl]propyl ester
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term ,or -20 °C for long term
• InChI: InChI=1S/C32H35N3O4/c1-19(2)39-18-20-10-11-26-23(14-20)29-25-16-33-32(37)30(25)28-22-9-6-5-8-21(22)15-24(28)31(29)35(26)12-7-13-38-27(36)17-34(3)4/h5-6,8-11,14,19H,7,12-13,15-18H2,1-4H3,(H,33,37)
• InChIKey: UHEBDUAFKQHUBV-UHFFFAOYSA-N
• SMILES: CC(C)OCC1=CC2=C(C=C1)N(C3=C4CC5=CC=CC=C5C4=C6C(=C23)CNC6=O)CCCOC(=O)CN(C)C

CEP-18770(CAT: I005957) is an orally bioavailable synthetic P2 threonine boronic acid proteasome inhibitor with potent antineoplastic activity. It selectively targets the chymotrypsin-like activity of the proteasome, inhibiting the degradation of proteins such as IkappaBalpha, a key inhibitor of NF-kappaB. This leads to the cytoplasmic sequestration of NF-kappaB, blocking its nuclear translocation and transcriptional activity, which promotes apoptotic cell death in tumor cells. Compared to bortezomib, CEP-18770 demonstrates reduced cytotoxicity in normal epithelial cells and bone marrow progenitors, offering a favorable safety profile. This compound is ideal for in vitro and in vivo cancer research, advancing proteasome-targeted therapeutic strategies.